Symptomatic systolic ventricular failure

[1]  R. Doughty,et al.  Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. , 1997, European heart journal.

[2]  Bertram Pitt,et al.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.

[3]  Australia..  Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease , 1997, The Lancet.

[4]  C M O'Connor,et al.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. , 1996, The New England journal of medicine.

[5]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[6]  K. Swedberg,et al.  What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. , 1996, European heart journal.

[7]  P C Deedwania,et al.  Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.

[8]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[9]  L. Wilkins.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.

[10]  A. Skene,et al.  Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators. , 1994, British heart journal.

[11]  H. Doval,et al.  Randomised trial of low-dose amiodarone in severe congestive heart failure , 1994, The Lancet.

[12]  M. Gheorghiade,et al.  WITHDRAWAL OF DIGOXIN FROM PATIENTS WITH CHRONIC HEART FAILURE TREATED WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS , 2010 .

[13]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[14]  M. Schumacher,et al.  Captopril versus digoxin in patients with coronary artery disease and mild heart failure. A prospective, double-blind, placebo-controlled multicenter study. The CADS Study Group. , 1993, Herz.

[15]  J. Brouwer,et al.  Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). , 1993, Journal of the American College of Cardiology.

[16]  B. Uretsky,et al.  Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. , 1993, Journal of the American College of Cardiology.

[17]  E. Fleck,et al.  Hemodynamic and Neurohormonal Effects of the Angiotensin II Antagonist Losartan in Patients With Congestive Heart Failure , 1993, Circulation.

[18]  R. Bain,et al.  Effects of vesnarinone on morbidity and mortality in patients with heart failure , 1993 .

[19]  D. Brutsaert,et al.  Diastolic failure: pathophysiology and therapeutic implications. , 1993, Journal of the American College of Cardiology.

[20]  V. Ferraris,et al.  Relationship between inotropic activity and phosphodiesterase inhibition for flosequinan and milrinone. , 1993, European journal of pharmacology.

[21]  J. Skoularigis,et al.  Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. , 1993, Journal of the American College of Cardiology.

[22]  G. Wittert,et al.  Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. , 1992, Circulation research.

[23]  M. Brodsky,et al.  Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. , 1992, Circulation.

[24]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[25]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[26]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[27]  H. Ikram,et al.  Xamoterol in severe heart failure , 1990, The Lancet.

[28]  B. Fletcher,et al.  Exercise testing and training with beta-adrenergic blockade: role of the drug washout period in "unmasking" a training effect. , 1989, American heart journal.

[29]  R. Schlant,et al.  A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. , 1989, The New England journal of medicine.

[30]  T. A. S. Group,et al.  DOUBLE-BLIND PLACEBO-CONTROLLED COMPARISON OF DIGOXIN AND XAMOTEROL IN CHRONIC HEART FAILURE , 1988, The Lancet.

[31]  M. Wilén,et al.  Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. , 1988, JAMA.

[32]  G. Sutton,et al.  DOUBLE-BLIND COMPARISON OF CAPTOPRIL ALONE AGAINST FRUSEMIDE PLUS AMILORIDE IN MILD HEART FAILURE , 1987, The Lancet.

[33]  P. Poole‐Wilson,et al.  Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. , 1987, British heart journal.

[34]  J. Hampton,et al.  SYMPTOMATIC ASSESSMENT OF PATIENTS WITH HEART FAILURE: DOUBLE-BLIND COMPARISON OF INCREASING DOSES OF DIURETICS AND CAPTOPRIL IN MODERATE HEART FAILURE , 1986, The Lancet.

[35]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[36]  T. Ryan,et al.  Acute and long-term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. , 1985, Journal of the American College of Cardiology.

[37]  F. Shellock,et al.  Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement. , 1985, Circulation.

[38]  M. Packer,et al.  Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. , 1984, Circulation.

[39]  B. W. East,et al.  Captopril in heart failure. A double blind controlled trial. , 1984, British heart journal.

[40]  D. Sharpe,et al.  Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. , 1984, Circulation.

[41]  B. Massie,et al.  Controlled Trial of Captopril in Chronic Heart Failure: A Rest and Exercise Hemodynamic Study , 1983, Circulation.

[42]  J. Cohn,et al.  Acute and Long‐term Response to an Oral Converting‐enzyme Inhibitor, Captopril, in Congestive Heart Failure , 1980, Circulation.

[43]  B. Brundage,et al.  Immediate and Sustained Hemodynamic and Clinical Improvement in Chronic Heart Failure by an Oral Angiotensin‐converting Enzyme Inhibitor , 1980, Circulation.

[44]  E. Sonnenblick,et al.  Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme. , 1979, The New England journal of medicine.